|Hutchison China Meditech
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Hutchison China Meditech Share Discussion Threads
Showing 901 to 924 of 925 messages
|The ADR's were given away, presumably based on the fact Investors were not prepared to pay what the Company wanted. AIM Shareholders were treated badly IMO although I suspect the Company is aware that a) there are very few Shareholders and b) people need to treat this as a very long term investment.
I'd be happy if we de-listed from AIM IF there was an appetite amongst U.S. Institutional Investors for our Company, which there isn't at the moment.
I suspect U.S. Investors are very wary about investing in a Chinese Biotech, even though its effectively majority owned and run by Hutchison Whampoa.
Having said all of that I can't see us staying at circa £1bn when we have revenues in the low $ billions and earnings in the hundreds of $ millions.|
|I didn't predict any bounce in biotechs,I simply pointed out that the sector had enjoyed a recent rally in which HCM hadn't participated.Anyway,HCM isn't around £20,its 10% lower than that if ones going to scrutinise sector and stock.My annoyance lies in the fact that I got suckered into buying on the ADR ramp.I sold half of my holding months ago.I think there's every possibility that HCM will follow GWP and decamp from the AIM market.It costs about £250,000 a year to pay for an AIM listing plus all the trimmings.Why do they bother.Future funding will almost certainly be focused on the US.Don't pay any attention to me,I only wish to chastise myself for awful timing in buying this stock.|
|Hi steeplejack. You appear to be a little negative on hcm at the moment. In August you were saying how well the Nasdaq biotech index was doing and the article you posted was bullish for it's future. In fact it has dropped 10.8% since then. HCM has remained fairly level at around £20 over the past two months while the Nasdaq pharma index has dropped around 7.4%. And as for the 'pitiful AIM volumes' I don't see volumes on the Nasdaq anything to shout about. Happy to be corrected if I'm wrong.|
|I see that GWP has announced its intent to abandon an AIM listing come December and concentrate on its NASDAQ listing.If this company considers doing the same(which I think it might given the pitiful AIM volumes)I fear Chi-Med might crystallise a capital loss for some......me included!They don't need listing in the UK by all accounts.The NASDAQ listing did UK holders a great disservice.If they abandon a UK listing,it'll be the nail in the coffin.|
|And all those revenues and profits are only of interest if shareholders receive a dividend.....which they don't here.|
|Despite that I assume when we have revenues in the billions and earnings in the hundreds of millions we will have a market cap many times of what it is today.
Jiangsu Hengrui is a reasonable Company to compare to.|
|That is a very good pint steeplejack. Thank You.|
|US institutions won't buy because one of the attractions of biotech is that if a company gets lucky and discovers something big,it will nine times out of ten get taken over!This stock is takeover proof.|
He still has a large holding and maybe he sold to fund something such as a house purchase but the price drift is frustrating, especially the fact we are down 16% on NASDAQ since the IPO.
Almost no U.S. institutional Investors on board (similar to Beigene). My conclusion is the big U.S. Specialist Funds will not invest because we are a Chinese Company, albeit controlled by a Hong Kong conglomerate.|
|Non- exec share sale.He's got bored like the rest of us.|
|Lots of deals taking place, the latest one is Shire to take over Radius. We must get pipeline news shortly...|
|surely due some news on the pipeline by now|
|got excited there, someone else posting on the board, only to find them snoring!
Interesting that the words shortly, imminently and soon have an entire new meaning of the words compared to their normal use.|
|Zzzz Zzzz zzz|
|Big news due very shortly eg. in the next 6 months!!|
|Lots of news due, mainly on the pipeline, especially Savolitinib and Fruquintinib. I wonder how the initial presentations and meetings went with the FDA?|
|good for me, I continue to buy but I get your point|
|Right shoulder of h+s formation?looks like it, not good if so|
|Mr Nash's family buy yet again, clearly he knows how big we will be in the coming decade|
|Anyone come across any US-based discussion forums for HCM?|
|True but the tide appears to be turning.The biotech investment trusts are well off their lows.This stock is still suffering the after effects of a poorly handled ADR issue.Certainly as far as UK holders are concerned.|
|Then again Biotech & Biopharma have been out of favour so far this year in the U.S. markets|
|Zzzzzz zzzzzz zzzz|